Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis
Carregando...
Citações na Scopus
96
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.29, n.6, p.1091-1095, 2015
Resumo
BackgroundAtopic dermatitis (AD) in adults and profile of skin barrier proteins and inflammatory cytokines. ObjectiveEvaluation of the expression of skin barrier proteins such as filaggrin, claudins 1 and 4 and of circulating inflammatory cytokines (Th1/Th2/Th17) in adults with AD. MethodsThirty-three adult patients with AD diagnosed according to the Hanifin & Rajkacriteria, and 25 healthy controls were enrolled in the study. AD severity was measured by Eczema Area and Severity Index (EASI). Laboratory assays included immunohistochemistry analysis of skin barrier proteins, such as filaggrin, claudins 1 and 4 and interleukin-17 (IL-17) from skin samples and determination of circulating cytokine levels (IL-2, 4, 5, 6, 10, 17A, TNF and IFN-) by flow cytometry (Cytometric Bead Array). ResultsWe observed a reduced expression of filaggrin and claudin 1 in lesional skin of AD patients, when compared to controls. There was an inverse correlation of filaggrin expression and disease severity. In addition, IL-17 expression was enhanced in AD patients. Similarly, higher levels of inflammatory cytokines (IL-2, 5, 6, 10, 17A and IFN-) were found in AD patients. ConclusionOur data reinforce the role of an altered skin barrier in the pathogenesis of AD. Our results show not only reduced expression of filaggrin and claudin 1 in lesional atopic skin but also inverse correlation of filaggrin expression and disease severity. Moreover, elevation of in situ IL-17 and of circulating interleukin levels in AD emphasize the systemic, inflammatory profile of this defective skin barrier dermatosis.
Palavras-chave
Referências
- Addor FAS, 2012, INT J DERMATOL, V51, P672, DOI 10.1111/j.1365-4632.2011.05176.x
- Breuer K, 2005, CLIN EXP ALLERGY, V35, P1088, DOI 10.1111/j.1365-2222.2005.02295.x
- DesBenedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773
- Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010
- Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022
- Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358
- Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x
- Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x
- HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44
- Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040
- Jensen JM, 2009, J ALLERGY CLIN IMMUN, V124, pR19, DOI 10.1016/j.jaci.2009.07.015
- Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111
- Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563
- Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564
- Nelhubel GA, 2014, PATHOL ONCOL RES, V20, P99, DOI 10.1007/s12253-013-9665-6
- Niebuhr M, 2011, INFECT IMMUN, V79, P1615, DOI 10.1128/IAI.00958-10
- Orfali RL, 2013, REV ASSOC MED BRAS, V59, P270, DOI 10.1016/j.ramb.2012.12.004
- Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042
- Pagliari C, 2011, MICROB PATHOGENESIS, V50, P263, DOI 10.1016/j.micpath.2010.12.008
- Prasad K, 2012, J MED SYST, V36, P2621, DOI 10.1007/s10916-011-9737-7
- Rowe SM, 2009, BIODRUGS, V23, P165, DOI 10.2165/00063030-200923030-00003
- Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743
- Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414
- Wichmann K, 2009, BRIT J DERMATOL, V161, P300, DOI 10.1111/j.1365-2133.2009.09229.x
- Wolf R, 2012, CLIN DERMATOL, V30, P329, DOI 10.1016/j.clindermatol.2011.08.023